Abecma in India

Abecma - overview

Abecma (idecabtagene vicleucel) is manufactured by BMS/2seventy and indicated for Multiple myeloma. It is a CAR-T (BCMA) approved by the US FDA in 2021 and may be accessible to patients in India through a Named Patient Program or personal-import pathway.

Access in India

India's CDSCO permits import of unapproved drugs under Rule 36 for personal use by patients with a prescription from a registered medical practitioner. Named Patient import is common for rare-disease indications.

How Reserve Meds coordinates access in India

1. Patient or treating physician submits a request.
2. We verify clinical appropriateness and India-specific eligibility.
3. Treating physician in India issues prescription and clinical justification.
4. Country-specific NPP/personal-import forms are prepared and filed.
5. We source Abecma from a DSCSA-compliant US specialty wholesaler.
6. Cold-chain shipment to the patient's physician or hospital pharmacy in India.

Typical timeline for India

End-to-end, most requests are completed in 2-6 weeks. India's tier 1 regulatory maturity typically supports fast processing times.

What patients and physicians in India ask

• Is the pathway legal in India? Yes - it operates under India's established NPP or personal-import framework.
• Does my insurance cover it? Typically no for NPP drugs; patient prepayment is standard.
• What physician credentials do I need? A licensed physician in India able to issue the prescription and clinical justification.
• What if the drug is in shortage? We will inform you upfront and decline rather than promise what we cannot deliver.
• Can I re-supply? Yes - for chronic therapies we arrange ongoing re-supply.

Start a request for Abecma in India

Join the Abecma waitlist